DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for chondrocalcinosis — screening already-approved drugs against its 30-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleChondrocalcinosis maps to a 30-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for chondrocalcinosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
fucosyltransferase 9 (FUT9) — FUT9 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gdpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8D0U · 1.29 Å · ligand GUANOSINE-5'-DIPHOSPHATE (GDP). Experimental structure, not a prediction.
What the evidence adds up to
In a series of 72 patients with articular chondrocalcinosis, 37 had polyarticular involvement. Twenty-eight of those patients, including 19 from different family groups, were natives of the Chiloé island group. Members of one of the six families had unusually severe disease with deformities, and one had bony ankylosis of multiple joints. Pathologic findings in both acute and chronic stages were presented, including some severe changes not previously described.
In a Quebec family, articular chondrocalcinosis was documented in 9 members across 3 generations. No associated or secondary forms were found. Clinical manifestations appeared early in life, and extensive radiologic involvement was apparent. Genetic transmission was dominant, either autosomal or sex-linked, and not related to the HLA system.
A 42-year-old woman presented with cervicalgia and a firm mass at the occipitocervical region 28 years after suboccipital craniotomy. Imaging revealed a calcified lesion in the scar. Tumorectomy and histopathology showed exuberant tumoral chondrocalcinosis. No secondary cause was found. The authors concluded that identification of chondrocalcinosis beyond the cervical region is very rare, and that surgery appears to be the treatment of choice for this form.
No controlled trials, no drug interventions, and no data on response rates or survival are reported in these abstracts. What is missing is any prospective study of treatment, any randomised trial design, any patient stratification by genetic subtype, and any funding for such work.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractAbstract From our series of 72 patients with articular chondrocalcinosis, 37 who presented polyarticular involvement are described. Twenty‐eight patients, including 19 aggregated within different family groups, are natives of the Chiloé island group. Members of 1 of the 6 families had unusually severe disease with deformities, and 1 had bony ankylosis of multiple joints. Pathologic findings in both the acute and the chronic stages of the joint disease are presented, particularly, some severe changes that have not been described previously.
AbstractThe existence of articular chondrocalcinosis was documented in 9 members of 3 generations of a Quebec family. No associated or secondary forms of the disease were found. The clinical manifestations appeared early in life, and extensive radiologic involvement was apparent. We determined that genetic transmission was dominant, either autosomal or sex-linked, and not related to the HLA system.
CERVICAL TUMORAL CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE 28 YEARS AFTER SUBOCCIPITAL CRANIOTOMY
AbstractOBJECTIVE: To describe a rare case of tumoral cervical chondrocalcinosis that appeared 28 years after the patient had undergone suboccipital craniotomy. CLINICAL PRESENTATION: A 42-year-old woman suffered from cervicalgia associated with a firm mass at the occipitocervical region. Plain x-ray and computed tomographic and magnetic resonance images revealed a calcified lesion in a scar from a previous suboccipital craniotomy. INTERVENTION: The patient underwent tumorectomy and histopathology, which revealed an exuberant tumoral chondrocalcinosis. Laboratory test results revealed no secondary cause for the chondrocalcinosis. CONCLUSION: Identification of chondrocalcinosis beyond the cervical region is very rare. Localization of chondrocalcinosis in a scar from a previous suboccipital craniotomy has not been previously reported. Surgery appears to be the treatment of choice for this form of chondrocalcinosis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
